A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

被引:745
作者
Passamonti, Francesco [1 ]
Cervantes, Francisco [2 ]
Vannucchi, Alessandro Maria [3 ]
Morra, Enrica [4 ]
Rumi, Elisa [1 ]
Pereira, Arturo [2 ]
Guglielmelli, Paola [3 ]
Pungolino, Ester [4 ]
Caramella, Marianna [4 ]
Maffioli, Margherita [2 ]
Pascutto, Cristiana [1 ]
Lazzarino, Mario [1 ]
Cazzola, Mario [1 ]
Tefferi, Ayalew [5 ]
机构
[1] Univ Pavia & Fdn, Ist Ricovero & Cura Carattere Sci, Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[2] Univ Barcelona, Dept Hematol, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
[3] Univ Florence, Ist Toscano Tumori, Unita Funz Ematol, Dipartimento Area Crit Med Chirug, Florence, Italy
[4] Osped Niguarda Ca Granda, Div Hematol, Milan, Italy
[5] Mayo Clin, Div Hematol, Dept Med, Rochester, MN USA
关键词
AGNOGENIC MYELOID METAPLASIA; STEM-CELL TRANSPLANTATION; WORLD-HEALTH-ORGANIZATION; POST-POLYCYTHEMIA VERA; CYTOGENETIC ABNORMALITIES; ESSENTIAL THROMBOCYTHEMIA; SCORING SYSTEM; IDIOPATHIC MYELOFIBROSIS; DIAGNOSIS; DISORDERS;
D O I
10.1182/blood-2009-09-245837
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 x 10(9)/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making. (Blood. 2010;115:1703-1708)
引用
收藏
页码:1703 / 1708
页数:6
相关论文
共 30 条
  • [1] Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
    Barosi, G.
    Mesa, R. A.
    Thiele, J.
    Cervantes, F.
    Campbell, P. J.
    Verstovsek, S.
    Dupriez, B.
    Levine, R. L.
    Passamonti, F.
    Gotlib, J.
    Reilly, J. T.
    Vannucchi, A. M.
    Hanson, C. A.
    Solberg, L. A.
    Orazi, A.
    Tefferi, A.
    [J]. LEUKEMIA, 2008, 22 (02) : 437 - 438
  • [2] A PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA
    BAROSI, G
    BERZUINI, C
    LIBERATO, LN
    COSTA, A
    POLINO, G
    ASCARI, E
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (04) : 397 - 401
  • [3] Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis
    Cervantes, F
    Pereira, A
    Esteve, J
    Rafel, M
    Cobo, F
    Rozman, C
    Montserrat, E
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (03) : 635 - 640
  • [4] New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    Cervantes, Francisco
    Dupriez, Brigitte
    Pereira, Arturo
    Passamonti, Francesco
    Reilly, John T.
    Morra, Enrica
    Vannucchi, Alessandro M.
    Mesa, Ruben A.
    Demory, Jean-Loup
    Barosi, Giovanni
    Rumi, Elisa
    Tefferi, Ayalew
    [J]. BLOOD, 2009, 113 (13) : 2895 - 2901
  • [5] Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    Deeg, HJ
    Gooley, TA
    Flowers, MED
    Sale, GE
    Slattery, JT
    Anasetti, C
    Chauncey, TR
    Doney, K
    Georges, GE
    Kiem, HP
    Martin, PJ
    Petersdorf, EW
    Radich, J
    Sanders, JE
    Sandmaier, BM
    Warren, EH
    Witherspoon, RP
    Storb, R
    Appelbaum, FR
    [J]. BLOOD, 2003, 102 (12) : 3912 - 3918
  • [6] Dupriez B, 1996, BLOOD, V88, P1013
  • [7] Guardiola P, 1999, BLOOD, V93, P2831
  • [8] Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
    Guglielmelli, Paola
    Barosi, Giovanni
    Specchia, Giorgina
    Rambaldi, Alessandro
    Lo Coco, Francesco
    Antonioli, Elisabetta
    Pieri, Lisa
    Pancrazzi, Alessandro
    Ponziani, Vanessa
    Delaini, Federica
    Longo, Giovanni
    Ammatuna, Emanuele
    Liso, Vincenzo
    Bosi, Alberto
    Barbui, Tiziano
    Vannucchi, Alessandro M.
    [J]. BLOOD, 2009, 114 (08) : 1477 - 1483
  • [9] Karyotype complements the International Prognostic Scoring System for primary myelofibrosis
    Hussein, Kebede
    Huang, Jocelin
    Lasho, Terra
    Pardanani, Animesh
    Mesa, Ruben A.
    Williamson, Cynthia M.
    Ketterling, Rhett P.
    Hanson, Curtis A.
    Van Dyke, Daniel L.
    Tefferi, Ayalew
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (04) : 255 - 259
  • [10] A gain-of-function mutation of JAK2 in myeloproliferative disorders
    Kralovics, R
    Passamonti, F
    Buser, AS
    Teo, S
    Tiedt, R
    Passweg, JR
    Tichelli, A
    Cazzola, M
    Skoda, RC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) : 1779 - 1790